TechMap Live › By country › China
AI & machine learningmedium impactMindRank Advances Oral GLP-1 to Phase III in Four Years
· Hangzhou, China · Asia-Pacific
MindRank, a Hangzhou-based AI drug developer, reports its oral GLP-1 candidate has progressed from program initiation to Phase III trials in roughly four and a half years with $23 million in research spending.
- Topic
- AI & machine learning
- Location
- Hangzhou, China (30.274°, 120.155°)
- Region
- Asia-Pacific
- Impact
- medium
- Reported value
- $23M
- Reported by
- The Next Web
This page was generated automatically by TechMap Live from a public news report published by The Next Web. Coordinates and impact level are estimates — an event is usually pinned at a company's headquarters or launch site. This is an aggregation of news coverage, not original reporting — read the original report before relying on it.
Latest events
- Microsoft Paint and Photos apps add invisible watermark to AI-generated content
- Aikido Security discovers Claude Opus 4.6 vulnerability in gym booking
- Nothing releases beta of Nothing OS 5.0 based on Android 17
- Aldi introduces Shark cordless vacuum
- OpenAI's first AI chip outperforms Nvidia in efficiency
- Apple deprecates hdiutil in macOS 27, replaced by diskutil
- Fairphone launches Gen 6+ modular smartphone
- Ikea and Xbox launch gamer-friendly furniture line